The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

51Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.

Cite

CITATION STYLE

APA

Cohen, P. A., Donini, C. F., Nguyen, N. T., Lincet, H., & Vendrell, J. A. (2015). The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Oncotarget, 6(39), 41566–41581. https://doi.org/10.18632/oncotarget.5893

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free